PDF(Pubmed)
Abstract：
UNASSIGNED: Meningiomas are slow-growing brain neoplasms classified into three grades based on morphological criteria. While these grades are simple, they do not always correlate with patient outcomes. This study aimed to evaluate the status of estrogen receptor (ER), progesterone receptor (PR), and proliferation marker Ki-67/molecular immunology borstel-1 (MIB-1) in the three grades of meningioma.
UNASSIGNED: We evaluated the data of meningioma patients who were seen in our tertiary center over 10 years-8.5 years retrospectively and 1.5 years prospectively. Their archival hematoxylin and eosin stained slides were reviewed and re-graded according to the World Health Organization 2021 criteria. Immunohistochemical analysis for ER, PR, and Ki-67 was performed on all grade 2 and grade 3 meningiomas and 30 cases of grade 1 formalin-fixed, paraffin-embedded samples.
UNASSIGNED: Of the 276 cases included in the study, there were 231 (83.7%) cases of grade 1 meningioma, 34 (12.3%) cases of grade 2, and 11 (4.0%) cases of grade 3. ER was positive in 26.0% of grade 1 tumors, 5.8% of grade 2, and 0.0% of grade 3. PR was positive in 70.0% of grade 1 tumors, 20.0% of grade 2, and 18.0% of grade 3. The Ki-67/MIB-1 labeling index (LI) was 2.1 in grade 1, 6.3 in grade 2, and 13.4 in grade 3 tumors. For both PR and Ki-67, the differences between grades 1, 2, and 3 tumors were significant (p < 0.001). There was a significant inverse relationship between mean Ki-67 LI and PR status, with increasing grade of tumor.
UNASSIGNED: Ki-67/MIB-1 LI has significant positive correlations with meningioma grade and its recurrence, which makes it a useful auxiliary method for the routine assessment of meningiomas, especially in patients with borderline atypia. The expression of PR, on the other hand, is a positive prognostic indicator and has a substantial correlation with histological grade. In cases of subtotal resection, high proliferative/recurrence rates, and borderline histopathology, the PR status in combination with the MIB-1 LI can offer insights into the behavior and the recurrence probability of a meningioma.
UNASSIGNED: We evaluated the data of meningioma patients who were seen in our tertiary center over 10 years-8.5 years retrospectively and 1.5 years prospectively. Their archival hematoxylin and eosin stained slides were reviewed and re-graded according to the World Health Organization 2021 criteria. Immunohistochemical analysis for ER, PR, and Ki-67 was performed on all grade 2 and grade 3 meningiomas and 30 cases of grade 1 formalin-fixed, paraffin-embedded samples.
UNASSIGNED: Of the 276 cases included in the study, there were 231 (83.7%) cases of grade 1 meningioma, 34 (12.3%) cases of grade 2, and 11 (4.0%) cases of grade 3. ER was positive in 26.0% of grade 1 tumors, 5.8% of grade 2, and 0.0% of grade 3. PR was positive in 70.0% of grade 1 tumors, 20.0% of grade 2, and 18.0% of grade 3. The Ki-67/MIB-1 labeling index (LI) was 2.1 in grade 1, 6.3 in grade 2, and 13.4 in grade 3 tumors. For both PR and Ki-67, the differences between grades 1, 2, and 3 tumors were significant (p < 0.001). There was a significant inverse relationship between mean Ki-67 LI and PR status, with increasing grade of tumor.
UNASSIGNED: Ki-67/MIB-1 LI has significant positive correlations with meningioma grade and its recurrence, which makes it a useful auxiliary method for the routine assessment of meningiomas, especially in patients with borderline atypia. The expression of PR, on the other hand, is a positive prognostic indicator and has a substantial correlation with histological grade. In cases of subtotal resection, high proliferative/recurrence rates, and borderline histopathology, the PR status in combination with the MIB-1 LI can offer insights into the behavior and the recurrence probability of a meningioma.
摘要：
■脑膜瘤是根据形态学标准分为三个等级的缓慢生长的脑肿瘤。虽然这些成绩很简单，它们并不总是与患者预后相关。本研究旨在评估雌激素受体（ER）的状态，孕激素受体（PR），和增殖标记Ki-67/分子免疫学borstel-1（MIB-1）在三个级别的脑膜瘤中。
■我们评估了在我们的三级中心观察的脑膜瘤患者的数据，这些患者在10年-8.5年和1.5年的时间进行了回顾性分析。根据世界卫生组织2021年的标准，对其存档的苏木精和曙红染色的载玻片进行了审查和重新分级。ER的免疫组织化学分析，PR,对所有2级和3级脑膜瘤和30例福尔马林固定的1级脑膜瘤进行Ki-67，石蜡包埋的样品。
■在纳入研究的276例病例中，1级脑膜瘤231例(83.7%),2级34例（12.3%），3级11例（4.0%）。ER在26.0％的1级肿瘤中呈阳性，2级的5.8％，3级的0.0％。70.0%的1级肿瘤PR阳性,2级的20.0%，3级的18.0%。Ki-67/MIB-1标记指数（LI）在1级肿瘤中为2.1，在2级肿瘤中为6.3，在3级肿瘤中为13.4。对于PR和Ki-67，1级、2级和3级肿瘤之间的差异是显著的(p<0.001)。平均Ki-67LI和PR状态之间存在显著的反比关系，随着肿瘤分级的增加。
■Ki-67/MIB-1LI与脑膜瘤分级及其复发呈显著正相关，这使得它成为脑膜瘤常规评估的有用辅助方法，尤其是有临界异型的患者。PR的表达,另一方面,是一个积极的预后指标，并与组织学分级有实质性的相关性。在次全切除的情况下，高增殖/复发率，和临界组织病理学，PR状态结合MIB-1LI可以提供对脑膜瘤行为和复发概率的见解。
■我们评估了在我们的三级中心观察的脑膜瘤患者的数据，这些患者在10年-8.5年和1.5年的时间进行了回顾性分析。根据世界卫生组织2021年的标准，对其存档的苏木精和曙红染色的载玻片进行了审查和重新分级。ER的免疫组织化学分析，PR,对所有2级和3级脑膜瘤和30例福尔马林固定的1级脑膜瘤进行Ki-67，石蜡包埋的样品。
■在纳入研究的276例病例中，1级脑膜瘤231例(83.7%),2级34例（12.3%），3级11例（4.0%）。ER在26.0％的1级肿瘤中呈阳性，2级的5.8％，3级的0.0％。70.0%的1级肿瘤PR阳性,2级的20.0%，3级的18.0%。Ki-67/MIB-1标记指数（LI）在1级肿瘤中为2.1，在2级肿瘤中为6.3，在3级肿瘤中为13.4。对于PR和Ki-67，1级、2级和3级肿瘤之间的差异是显著的(p<0.001)。平均Ki-67LI和PR状态之间存在显著的反比关系，随着肿瘤分级的增加。
■Ki-67/MIB-1LI与脑膜瘤分级及其复发呈显著正相关，这使得它成为脑膜瘤常规评估的有用辅助方法，尤其是有临界异型的患者。PR的表达,另一方面,是一个积极的预后指标，并与组织学分级有实质性的相关性。在次全切除的情况下，高增殖/复发率，和临界组织病理学，PR状态结合MIB-1LI可以提供对脑膜瘤行为和复发概率的见解。
